Chapter 8: Anxiety, Trauma, and Treatment

Anxiety, Trauma, and Treatment conditions overlap substantially with major depressive disorder in symptoms such as sleep disturbance, attentional difficulties, fatigue, and alterations in arousal and motor activity. The neurobiological basis of anxiety involves two distinct circuits: fear-based symptoms including panic and phobic responses are mediated through an amygdala-centered network that regulates motor responses (fight, flight, or freeze reactions), endocrine function (hypothalamic-pituitary-adrenal axis activation and cortisol release), respiratory patterns, and autonomic output via noradrenergic pathways through the locus coeruleus affecting heart rate and blood pressure. Worry and apprehensive anticipation, by contrast, appear linked to cortico-striato-thalamo-cortical feedback loops. Pharmacological interventions target specific neurotransmitter systems including serotonergic, noradrenergic, GABAergic, and ion channel mechanisms. Benzodiazepines provide rapid symptom relief by enhancing inhibitory GABA signaling in both the amygdala and cortico-striato-thalamo-cortical circuits. First-line treatments such as serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors increase availability of serotonin to both fear and worry circuits. Alpha-2-delta ligands block presynaptic voltage-sensitive calcium channels, thereby reducing excitatory glutamate release and suppressing both fear and worry responses. Management of hyperarousal states employs alpha-1 antagonists or norepinephrine transporter inhibitors to reduce excessive noradrenergic activity. Emerging therapeutic approaches target learned fear mechanisms by leveraging extinction learning, wherein ventromedial prefrontal cortex and hippocampal structures provide inhibitory control over amygdala-driven fear responses during exposure-based interventions. Novel strategies aim to enhance extinction learning through N-methyl-D-aspartate receptor modulation during psychotherapy or to interfere with memory reconsolidation using beta blockers and dissociative agents, offering potential pathways to durable symptom reduction in chronic trauma-related presentations.